Research Article
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
Table 4
Quality of life’s evolution over time. QLQ-C30 questionnaire.
| | Domain | Baseline (N = 87) | Treatment maintenance | value | | Month 3 (N = 27) | Month 6 (N = 17) | Month 12 (N = 15) | | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| | Global health status | 56.9 (19.2) | 64.1 (21.3) | 63.2 (24.1) | 72.8 (13.5) | 0.03 | | Physical functioning | 80.0 (24.6) | 87.2 (20.8) | 86.3 (21.4) | 88.4 (15.0) | 0.46 | | Role functioning | 77.6 (29.8) | 87.7 (26.0) | 86.3 (26.5) | 86.7 (21.1) | 0.23 | | Emotional functioning | 73.9 (25.7) | 76.3 (24.9) | 78.4 (26.4) | 81.7 (16.4) | 0.54 | | Cognitive functioning | 90.2 (21.3) | 95.5 (8.9) | 96.1 (7.3) | 93.3 (12.3) | 0.37 | | Social functioning | 76.4 (30.7) | 88.5 (15.5) | 84.3 (26.7) | 81.1 (30.1) | 0.36 | | Fatigue | 26.2 (25.0) | 19.8 (26.6) | 13.7 (21.0) | 16.3 (15.1) | 0.93 | | Nausea | 13.6 (20.3) | 4.3 (7.4) | 3.9 (7.3) | 4.4 (9.9) | 0.009 | | Pain | 26.2 (25.7) | 20.4 (26.7) | 19.6 (27.8) | 17.8 (23.1) | 0.24 | | Dyspnea | 15.7 (24.3) | 8.6 (19.8) | 5.9 (13.1) | 11.1 (16.3) | 0.26 | | Insomnia | 32.6 (29.2) | 17.3 (19.3) | 17.6 (26.7) | 15.6 (17.2) | 0.04 | | Appetite loss | 28.4 (29.4) | 23.5 (29.0) | 25.5 (25.1) | 24.4 (23.5) | 0.12 | | Constipation | 19.9 (30.7) | 6.4 (21.1) | 2.0 (8.1) | 8.9 (19.8) | 0.04 | | Diarrhea | 3.4 (10.2) | 1.3 (6.5) | 2.0 (8.1) | 0.0 (0.0) | 0.10 | | Financial difficulties | 34.1 (33.3) | 24.4 (20.1) | 33.3 (31.4) | 24.4 (29.5) | 0.10 |
|
|
Statistically significant values according to the ANOVA test for repeated measurements. SD: standard deviation. |
